Key facts
- · Type: Amendment first sale 2025-11-25 · Amount sold: $55.74M · Total offering: $121.48M · SEC filing
- · Type: New offering first sale 2025-11-25 · Amount sold: $55.74M · Total offering: $121.48M · SEC filing
- · Type: New offering first sale 2025-09-12 · Amount sold: $2.30M · Total offering: $2.30M · SEC filing
- · Type: New offering first sale 2025-02-26 · Amount sold: $3.30M · Total offering: $3.30M · SEC filing
- · Type: New offering first sale 2023-12-28 · Amount sold: $10M · Total offering: $10M · SEC filing
Is Claris Biotherapeutics, Inc. a real, registered company?
Claris Biotherapeutics, Inc. is a registered filer with the SEC (CIK 1809726) and has filed since 2023-10-24. 6 filings are on record, the latest on 2026-08-12.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
Who runs Claris Biotherapeutics, Inc.?
Claris Biotherapeutics, Inc.'s filings name Clarke Atwell, Kenneth Harrison, Marc de Garidel and 9 more as its officers, directors or promoters.
How much has Claris Biotherapeutics, Inc. raised?
Its new offerings report $71.34M sold across 4 offerings, as its own filings state.
Run the free check on Claris Biotherapeutics, Inc. →
HALF MOON BAY, CALIFORNIA
Biotechnology
6
$71.34M
Every filing
| Filed | Type | Amount sold | Total offering | Records |
|---|---|---|---|---|
| 2026-08-12 | Amendment first sale 2025-11-25 | $55.74M | $121.48M | SEC filing |
| 2026-08-07 | New offering first sale 2025-11-25 | $55.74M | $121.48M | details · SEC filing |
| 2025-09-22 | New offering first sale 2025-09-12 | $2.30M | $2.30M | details · SEC filing |
| 2025-03-07 | New offering first sale 2025-02-26 | $3.30M | $3.30M | details · SEC filing |
| 2024-01-08 | New offering first sale 2023-12-28 | $10M | $10M | SEC filing |
| 2023-10-24 | Amendment first sale 2020-04-13 | $44.50M | $44.50M | SEC filing |
Want the whole picture on Claris Biotherapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Claris Biotherapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Claris Biotherapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
How the total is counted: the amount sold on each new offering, added together. Amendments are left out, because an amendment restates an offering already counted. A filing whose figures have not been read yet shows a dash and adds nothing.
Every figure here is read from Claris Biotherapeutics, Inc.'s own filings with the SEC. The people those filings name are on the team page.